Partner
Amanda Murphy, Ph.D., brings over 17 years of experience to her life sciences intellectual property practice. As a U.S. patent attorney practicing in London, Amanda is ideally situated to counsel clients on their global patent strategies. Her practice includes patent application preparation and prosecution, pre-litigation portfolio and due diligence analyses, and contentious PTAB proceedings.
Amanda focuses on developing patent filing and prosecution strategies tailored to clients' worldwide business goals. She works with a wide range of clients, including small biotech startup companies, research foundations, and large publicly traded biotechnology and pharmaceutical companies.
Amanda prepares new patent applications, prosecutes U.S. and foreign applications, and represents appellants in ex parte appeals before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). She has also led clients through numerous reissue applications, inter partes and ex parte reexamination applications, and supplemental examination proceedings.
Amanda's extensive client counseling practice includes providing patentability, freedom-to-operate, infringement, and validity opinions. In addition, she represents petitioners and patent owners in inter partes review (IPR) and post grant review (PGR) proceedings before the PTAB.
Amanda has substantial experience in a wide variety of life sciences technologies, including antibodies and antibody drug conjugates; antiretrovirals and anticancer agents; biologics; blood clotting factors; cell signaling and signal transduction; diagnostic markers and detection assays; drug formulations; gene delivery systems, including AAV; gene editing technologies, including CRISPR; immunooncology; lipid nanoparticles; microbiome analysis and probiotics; nucleic acid modifications; peptide synthesis and protein purification; single-cell and single-molecule analysis; small molecule drugs; and vaccines.
Prior to joining Finnegan, Amanda received her Ph.D. from Cornell University, where she studied the molecular requirements for protein-lipid interactions during retroviral assembly and the lipid compositions of retroviral particles. She then gained significant experience as a technical specialist and a student associate at Finnegan during her studies in law school.
Amanda was recognized as a Best Mentor by Corporate Counsel's Women, Influence and Power in Law and currently serves on the firm's management committee.
Pfenex Inc. v. GlaxoSmithKline Biologicals SA
IPR2019-01027, -01028, PTAB
Capsugel Belgium NV v. Innercap Technologies, Inc.
IPR2013-00331, PTAB, Judges Crumbley, Elluru, Green
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Shire ViroPharma Inc. v. CSL Behring LLC
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
AbbVie Inc. v. Roxane Laboratories Inc.
1:12-cv-00457, D. Del., Judges Andrews, Burke
Alzheimer's Institute of America, Inc. v. Avid Radiopharmaceuticals
Member of litigation team for Avid in suit concerning amyloid beta technology and its use in animal models in searching for drugs to treat Alzheimer's disease (AD). Obtained jury verdict for Avid on issue of inventorship and patent ownership in 2012; affirmed by the Federal Circuit in 2013. Also obtained a finding of exceptional case, entitling Avid to an award of attorneys' fees. The trial disposed of a series of suits by the AIA against numerous companies involved in scientific research relating to Alzheimer's disease.
2:10-cv-06908, E.D. Pa., Judges Angell, Savage, Cohen (Special Master)
13-1544, 16-2647, Fed. Cir., Judges Hughes, Lourie, Moore, Newman, Plager
Event
U.S. Patent Applications for European Practitioners U.S. Patent Applications for European Practitioners
September 24, 2024
Virtual
Event
Patent Inventorship: Best Practices for Determination and Correction Patent Inventorship: Best Practices for Determination and Correction
July 18, 2024
Webinar
At the PTAB Blog
Board’s Failure to Meet Statutory Deadline to Issue Final Written Decision Does Not Result in Loss of Board’s Jurisdiction Board’s Failure to Meet Statutory Deadline to Issue Final Written Decision Does Not Result in Loss of Board’s Jurisdiction
July 16, 2024
Event
Obviousness-Type Double Patenting and USPTO Proposed Rules for Terminal Disclaimers Obviousness-Type Double Patenting and USPTO Proposed Rules for Terminal Disclaimers
July 2, 2024
Webinar
Event
U.S. Patent Applications for European Practitioners U.S. Patent Applications for European Practitioners
September 24, 2024
Virtual
Announcement
Finnegan Announces 2023 Mentors of the Year Finnegan Announces 2023 Mentors of the Year
December 29, 2023
Announcement
Finnegan Announces 2022 Mentors of the Year Finnegan Announces 2022 Mentors of the Year
December 30, 2022
Commentary
2022 Review: Big Guns Back the PTAB 2022 Review: Big Guns Back the PTAB
December 8, 2022
World Intellectual Property ReviewPress Release
Three Finnegan Partners Receive “Women, Influence, and Power in Law” Awards Three Finnegan Partners Receive “Women, Influence, and Power in Law” Awards
October 14, 2022
Press Release
Darren Jiron to Serve as Managing Partner of Finnegan’s London Office Darren Jiron to Serve as Managing Partner of Finnegan’s London Office
March 29, 2022
Announcement
Finnegan Announces 2020 Mentors of the Year Finnegan Announces 2020 Mentors of the Year
December 28, 2020
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.